Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part I)

Document Type

Article

Publication Date

3-31-2020

Publication Title

LinkedIn

Abstract

It is well-recognized that the COVID-19 pandemic has hit many ongoing clinical trials hard in many ways, including but not limited to:

  1. Government interventions including suppression and non-pharmaceutical interventions (NPIs) such as social distancing, lockdown, or quarantine.
  2. Supplies of study medications and availability of healthcare professionals and facilities for clinical and/or laboratory evaluations, treatment administration according to scheduled clinical visits typically specified in Table 1 of study protocols.

Link to Full Text

Share

COinS